Pramlintide (Symlin)
Synthetic amylin analog used adjunctively with insulin in type 1 and type 2 diabetes.
At a glance
What it is: Synthetic amylin analog used adjunctively with insulin in type 1 and type 2 diabetes..
Primary research applications:
- Type 1 diabetes (adjunct to insulin)
- Type 2 diabetes (adjunct to insulin)
- Glycemic control and modest weight effect
Editorial summary: Pramlintide is the original FDA-approved amylin analog (Symlin, 2005). It set the stage for cagrilintide and demonstrates the value of the amylin axis in glucose and weight control. Real-world use is limited by mealtime injection burden, but the pharmacology underpins the modern revival of amylin-class molecules.
- Class / structure
- Synthetic 37-amino-acid amylin analog with three proline substitutions
- Half-life
- ≈ 50 minutes
- First described
- 1990s
- Regulatory status
- FDA-approved (2005)
What is Pramlintide?
Pramlintide is a synthetic 37-amino-acid amylin analog that mimics the action of the endogenous beta-cell hormone amylin (also called islet amyloid polypeptide, IAPP), which is co-secreted with insulin from pancreatic beta cells.
Discovery and development
Pramlintide was developed as a stable analog of human amylin (which aggregates and is therefore unsuitable as a drug) by substituting three residues with proline — using the rat amylin sequence as the template. It was approved by the FDA as Symlin in 2005, the first and so far only amylin analog widely used in routine clinical practice.
Mechanism of action
Amylin's three primary actions are slowing of gastric emptying, suppression of postprandial glucagon, and central appetite reduction. In type 1 diabetes — where endogenous amylin is absent because beta cells have been destroyed — pramlintide replaces the missing hormone alongside insulin. In type 2 diabetes, it amplifies endogenous regulation.[1]
Pharmacokinetics
Pramlintide has a short ~50-minute half-life and is administered as a subcutaneous injection at meals (typically three times daily). Bioavailability after subcutaneous administration is approximately 30–40%.
What the research shows
The peer-reviewed literature on Pramlintide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Reduces HbA1c when added to insulin | Multiple Phase 3 RCTs | Supported |
| Produces modest weight loss | Diabetes Care studies; ~1–2 kg | Supported |
| Replaces lost amylin in type 1 diabetes | Mechanistic and supported by clinical data | Supported |
| Has been superseded as a stand-alone obesity therapy | Cagrilintide and CagriSema represent the modern revival | Mixed |
Reported user experiences
How the research describes administration
Pramlintide is administered subcutaneously immediately before major meals, with the insulin dose typically reduced by ~50% during initiation to avoid hypoglycemia.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Pramlintide is the original amylin analog and remains a useful adjunct in selected diabetes patients — particularly in type 1 disease where it physiologically replaces the missing beta-cell hormone. The modern relevance of pramlintide is also indirect: its existence and pharmacology pointed the way toward cagrilintide and the CagriSema combination, where amylin signaling is being repurposed for chronic obesity.
Frequently asked questions
Is pramlintide a GLP-1?
No. Pramlintide is an amylin analog, distinct from GLP-1. Both contribute to postprandial glucose control but through different receptors and pathways.
Why is pramlintide not used for obesity?
Its short half-life and mealtime dosing made it impractical for chronic weight management. The amylin pathway is now being revived for obesity through cagrilintide, which is engineered for once-weekly dosing.
References
- Lutz TA. Roles of amylin in satiation, adiposity and brain development. Forum Nutr. 2010;63:64-74. https://pubmed.ncbi.nlm.nih.gov/19955773/
- Whitehouse F, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide in type 1 diabetes. Diabetes Care. 2002;25(4):724-730. https://pubmed.ncbi.nlm.nih.gov/11919132/
- Hollander PA, et al. Pramlintide as an adjunct to insulin therapy in type 2 diabetes. Diabetes Care. 2003;26(3):784-790. https://pubmed.ncbi.nlm.nih.gov/12610038/